

FIRST LIGHT

RESEARCH

UTI AMC | TARGET: Rs 815 | -0% | HOLD

Equity flows lacklustre; valuations full – downgrade to HOLD

BOB ECONOMICS RESEARCH | CRUDE IMPORTS

Growing phase

LARSEN & TOUBRO | TARGET: Rs 3,000 | +17% | BUY

Stellar quarter; solid outlook

SBI LIFE | TARGET: Rs 1,500 | +15% | BUY

Mixed quarter; robust FY24 outlook maintained

AMBER ENTERPRISES | TARGET: Rs 2,500 | +10% | HOLD

Topline wavers, margins progressing

Daily macro indicators

Ticker	24-Jul	25-Jul	Chg (%)
US 10Y yield (%)	3.87	3.88	1bps
India 10Y yield (%)	7.07	7.10	3bps
USD/INR	81.83	81.87	(0.1)
Brent Crude (US\$/bbl)	82.7	83.6	1.1
Dow	35,411	35,438	0.1
Hang Seng	18,668	19,434	4.1
Sensex	66,385	66,356	0.0
India FI (US\$ mn)	21-Jul	24-Jul	Chg (\$ mn)
FI-D	27.5	20.0	(7.5)
FI-E	(171.3)	28.1	199.4

Source: Bank of Baroda Economics Research

SUMMARY

UTI AMC

- MTM gains boosted Q1 net profit growth to ~150% YoY whereas core net profit fell 25% YoY
- Equity and hybrid schemes (combined) saw outflows for four straight quarters due to flagship fund underperformance
- TP moves to Rs 815 (vs. Rs 800) as we raise FY24/FY25 PAT by 17%/2% to bake in higher other income; cut to HOLD on full valuations

[Click here for the full report.](#)

INDIA ECONOMICS: CRUDE IMPORTS

India is amongst top 5 importers of crude oil across the globe. Over 85% of India's demand for oil is met through imports on the back of the demand surge. India's import of crude oil has grown to 237mn tonne with Russia becoming one of biggest suppliers of the same in FY23. Share of Russia had grown to more than 20% in FY23 and as of FYTD'24 (Apr-May'23), it commands a share of around 39%. The Russia-Ukraine conflict resulted in easier availability of oil from Russia at a discounted price when compared with other countries or even international crude price. This note takes a look at the volume and price of crude oil in the span of 2-years.

[Click here for the full report.](#)

BOBCAPS Research
 research@bobcaps.in



LARSEN & TOUBRO

- Stellar Q1 led by inflows, execution and working capital efficiency; closed the quarter with a record Rs 4.1tn order book
- FY24 pipeline swells 34%, a key positive; return of capital through buyback and special dividends would aid ROE
- TP raised to Rs 3,000 (vs. Rs 2,630) on a higher core business EV/EBITDA multiple of 15x and valuation rollover; retain BUY

[Click here](#) for the full report.

SBI LIFE

- Q1 APE growth softened to 4% YoY as non-par business slowed; management optimistic of a rebound
- VNB margin sheds 160bps YoY but still strong at 28.8%; guided to stay rangebound in the near future
- TP revised to Rs 1,500 (vs. Rs 1,520) as we adjust estimates post Q1; maintain BUY

[Click here](#) for the full report.

AMBER ENTERPRISES

- Q1 revenue weak given the “worst of bad seasons”, though margins improved on a better product mix
- Strategic shift towards components working in favour of Amber; mobility business offers a large opportunity
- TP raised to Rs 2,500 (vs. Rs 2,260) on rollover; maintain HOLD

[Click here](#) for the full report.

HOLD
 TP: Rs 815 | ▼ 0%

UTI AMC

| NBFC

| 26 July 2023

Equity flows lacklustre; valuations full – downgrade to HOLD

- MTM gains boosted Q1 net profit growth to ~150% YoY whereas core net profit fell 25% YoY
- Equity and hybrid schemes (combined) saw outflows for four straight quarters due to flagship fund underperformance
- TP moves to Rs 815 (vs. Rs 800) as we raise FY24/FY25 PAT by 17%/2% to bake in higher other income; cut to HOLD on full valuations

Mohit Mangal

research@bobcaps.in

MTM gains boost profitability: UTI AMC’s Q1FY24 net profit soared ~150% YoY to Rs 2.3bn due to higher other income from MTM gains. Excluding these gains, core PAT declined 25% YoY. Revenue from operations dipped 2% YoY whereas operating expenses grew 12%, leading to poor profitability. To factor in higher other income, we raise our FY24/FY25 PAT estimates by 17%/2% to Rs 6.4bn/Rs 6.1bn.

Equity flows soft: UTI AMC saw its fourth consecutive quarter of outflows (and its highest) in equity and hybrid schemes combined at Rs 15bn in Q1. The culprit was sustained underperformance at one of its flagship funds which also impacted SIP sales. Management remained optimistic of turnaround in this scheme in coming quarters. Strong intake in other segments led to overall inflows of Rs 102bn.

Fortifying the distribution network: UTI AMC has a strong distribution network of ~63,700 mutual fund distributors (MFD), 166 UTI financial centres (UFC), and a large footprint in B30 cities, with plans to open 29 branches in FY24. B30 MAAUM totalled 22% of its AUM mix vs. 17% for the industry at end-Q1.

Operating expenses inch up: MF yield (calc) increased just 1bps QoQ to 37bps in Q1 and is expected to remain under pressure. Operating expenses grew 12% YoY to Rs 1.7bn as other expenses surged 26% to Rs 612mn. It also guided for a Rs 610mn-620mn quarterly other expense run-rate. The company indicated that it has hired 108 low-cost management trainees who will be able to replace higher-salaried retirees.

Downgrade to HOLD: We continue to value the company at an unchanged 17x FY25E P/E – a 20% discount to mean – as we balance the negatives of sustained outflows in high-yielding equity schemes, lower core profits, and weakness in UTI International (subsidiary) against the positives of strong overall flows and good alternative business. Following our upward earnings revision, our TP rises to Rs 815 (from Rs 800). The stock has run up 15% since 1 June and we see no levers for a further price upside – we thus move from BUY to HOLD.

Key changes

Target	Rating
▲	▼

Ticker/Price	UTIAM IN/Rs 815
Market cap	US\$ 1.3bn
Free float	34%
3M ADV	US\$ 2.9mn
52wk high/low	Rs 908/Rs 608
Promoter/FPI/DII	0%/6%/60%


Source: NSE | Price as of 26 Jul 2023

Key financials

Y/E 31 Mar	FY23A	FY24E	FY25E
Core PBT (Rs mn)	4,265	4,450	5,066
Core PBT (YoY)	(5.6)	4.3	13.9
Adj. net profit (Rs mn)	4,393	6,389	6,081
EPS (Rs)	34.4	50.3	47.9
Consensus EPS (Rs)	34.4	41.0	46.5
MCap/AAAUM (%)	4.3	3.9	3.5
ROAAAUM (bps)	18.4	24.3	20.8
ROE (%)	11.7	15.9	14.2
P/E (x)	23.7	16.2	17.0

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



CRUDE IMPORTS

26 July 2023

Growing phase

India is amongst top 5 importers of crude oil across the globe. Over 85% of India's demand for oil is met through imports on the back of the demand surge. India's import of crude oil has grown to 237mn tonne with Russia becoming one of biggest suppliers of the same in FY23. Share of Russia had grown to more than 20% in FY23 and as of FYTD'24 (Apr-May'23), it commands a share of around 39%. The Russia-Ukraine conflict resulted in easier availability of oil from Russia at a discounted price when compared with other countries or even international crude price. This note takes a look at the volume and price of crude oil in the span of 2-years.


Jahnvi Prabhakar
Economist

Import of Crude in the last 2-years

India relies on other countries to meet up its ever growing demand of crude and related products. The dependency on oil imports for domestic consumption as a result has been an uphill. On a volume basis, back in FY22, India's imported a total of 220mn tonnes of crude oil from the globe, with Russia having a meagre share of 2% for the year. On the other hand, India has imported a total of 237mn tonnes in FY23 and Russia's share has grown remarkably by over ten times to double digit level of 21.5%.

In terms of cost, Fig 1, highlights the price paid for 1 barrel of crude oil in US\$ from different countries in FY23. Russia was charging US\$ 84/bbl, while Nigeria was charging US\$ 108/bbl. The average international crude price for this period was at US\$ 95.1/bbl. With the beginning of the Russia-Ukraine conflict, the geo-political climate changed across the globe. It also brought to the fore the changing dynamics of the supply and demand pertaining to crude oil with certain countries imposing sanctions. Given this backdrop, Russia has turned out to be one of the largest supplier of oil to India by supplying oil at a much discounted price and even boosting profits for Indian firms.

Fig 1: Price paid for Crude across Countries in FY23



Source: CMIE, Bank of Baroda



BUY
 TP: Rs 3,000 | ▲ 17%

LARSEN & TOUBRO

| Capital Goods

| 26 July 2023

Stellar quarter; solid outlook

- Stellar Q1 led by inflows, execution and working capital efficiency; closed the quarter with a record Rs 4.1tn order book
- FY24 pipeline swells 34%, a key positive; return of capital through buyback and special dividends would aid ROE
- TP raised to Rs 3,000 (vs. Rs 2,630) on a higher core business EV/EBITDA multiple of 15x and valuation rollover; retain BUY

Vinod Chari | Swati Jhunjunwala
 research@bobcaps.in

Robust execution: Strong project execution in Q1FY24 aided revenue growth of 34% YoY to Rs 478.8bn (4Y CAGR at 12.7%), though legacy orders in the mix saw gross margin contract 570bps YoY to 35.8%. EBITDA margin at 10.2% slipped 80bps YoY while PAT grew 46% YoY to Rs 24.9bn. LT’s addressable pipeline has swelled 34% YoY to Rs 10tn, above the prospective level of Rs 9.7tn at end-FY23 despite the approaching elections (Apr-May’24), driven by hydrocarbons.

Margins to improve from H2FY24: The presence of legacy orders weighed on the core EBITDA margin in FY23 and in Q1. LT had executed ~60% of these projects as of FY23 and expects to complete the remaining 40% this fiscal year. Management thus expects EBITDA margin to rise ~50bps in FY24 and normalise to ~10% by FY25.

FY24 order and revenue guidance reiterated: LT maintained its FY24 order inflow and revenue growth guidance at 10-12% and 12-15% respectively. Working capital-to-sales improved to 17% in Q1 from the usual level of 20-22%, likely helped by good collections as well as strong order inflows, and management expects to maintain a range of 16-18% for the fiscal. The company ended FY23 with a record Rs 4tn order book, which has moved up to Rs 4.1tn with a book-to-bill ratio of ~3x.

Buyback to aid ROE: The return of capital through the recently announced Rs 100bn buyback along with special dividend would boost return ratios. LT retains its long-term vision of improving ROE to ~18% from the current 12% levels.

Subsidiary performance mixed: LT saw lower losses in the Hyderabad metro as daily ridership reached 0.42-0.44mn vs. 0.4mn in FY23. However, the Nabha power project was hit by lower power demand in Q1.

Maintain BUY: LT is a strong play on the India capex story and among our top sector picks. We retain BUY and raise our SOTP-based TP from Rs 2,630 to Rs 3,000 as we roll valuations over to Jun’25E and now value the core business ex-services at a higher 15x EV/EBITDA (14x earlier) given the enhanced ordering outlook. Our fair value includes Rs 900/sh for subsidiaries valued at 20% holdco discount.

Key changes

Target	Rating
▲	◀ ▶

Ticker/Price	LT IN/Rs 2,561
Market cap	US\$ 43.8bn
Free float	86%
3M ADV	US\$ 55.3mn
52wk high/low	Rs 2,638/Rs 1,742
Promoter/FPI/DII	0%/21%/35%


Source: NSE | Price as of 25 Jul 2023

Key financials

Y/E 31 Mar	FY23A	FY24E	FY25E
Total revenue (Rs mn)	18,33,407	21,32,402	24,04,205
EBITDA (Rs mn)	2,07,533	2,55,954	3,08,008
Adj. net profit (Rs mn)	1,03,347	1,39,039	1,75,195
Adj. EPS (Rs)	73.6	99.0	124.8
Consensus EPS (Rs)	73.6	93.5	115.0
Adj. ROAE (%)	12.0	14.8	16.7
Adj. P/E (x)	34.8	25.9	20.5
EV/EBITDA (x)	15.2	12.7	10.6
Adj. EPS growth (%)	20.6	34.5	26.0

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



BUY
 TP: Rs 1,500 | ▲ 15%

SBI LIFE

| Insurance

| 26 July 2023

Mixed quarter; robust FY24 outlook maintained

- Q1 APE growth softened to 4% YoY as non-par business slowed; management optimistic of a rebound
- VNB margin sheds 160bps YoY but still strong at 28.8%; guided to stay rangebound in the near future
- TP revised to Rs 1,500 (vs. Rs 1,520) as we adjust estimates post Q1; maintain BUY

Mohit Mangal

research@bobcaps.in

APE growth in lower single digits: SBI Life’s APE grew a mere 4% YoY in Q1FY24 to Rs 30bn owing to a 29% drop in non-par plans that were impacted by new tax regulation, largely negating ULIP sales growth of 17% YoY. Per management, non-par growth should bounce back in the remainder of FY24. Gross premium grew 19% YoY to Rs 136bn. The company maintained market leadership in the private life insurance space, commanding 22% NBP and 23% individual APE share at end-Q1.


Business skewed towards ULIPs: With non-par business dropping to Rs 5.8bn in Q1FY24, its share in total APE plummeted to 19% (vs. 28% in Q1FY23). ULIPs remained in focus at 53% of APE vs. 47%. Total protection business formed 12% share vs. 11% earlier. Individual protection APE grew 5% YoY in Q1 but was outdone by group protection at 33%. Demand for annuity products has been increasing and the segment grew 86% YoY, although on a lower base.

Change in product mix hurt VNB margin: SBI Life’s VNB was flat YoY in Q1 at Rs 8.7bn with a lower 28.8% margin (-160bps YoY) owing to a change in product mix. Management expects margins to remain rangebound at this level and we accordingly bake in estimates of 28.5% each (vs. 28%) for FY24/FY25. However, we pare VNB forecasts by 2%/0.4% owing to a 4%/2% cut in our APE estimates.

Mixed persistency results; cost ratios <11%: Persistency in the 13th month and 25th cohorts decreased by 60bps and 260bps YoY to 85.0% and 76.1% respectively in Q1, whereas that for the 61st month increased to 56.7% from 50.3%. The total cost ratio declined 40bps YoY to 10.8% at end-Q1 (opex ratio up 20bps YoY to 6.8% and commission ratio down 60bps to 4%), staying below that of listed private peers.

Maintain BUY: SBI Life is trading at 1.9x FY25E P/EV. Following our estimate changes, we arrive at a revised TP of Rs 1,500 (vs. Rs 1,520), valuing the stock at an unchanged 2.3x FY25E P/EV – a 10% discount to the long-term mean. We continue to like SBI Life for its market leadership, high VNB margins, efficient cost ratios and strong brand – maintain BUY.

Key changes



Ticker/Price	SBILIFE IN/Rs 1,301
Market cap	US\$ 15.9bn
Free float	45%
3M ADV	US\$ 16.5mn
52wk high/low	Rs 1,340/Rs 1,054
Promoter/FPI/DII	55%/24%/16%


Source: NSE | Price as of 25 Jul 2023

Key financials

Y/E 31 Mar	FY23P	FY24E	FY25E
NBP (Rs mn)	2,95,886	3,31,392	3,76,130
APE (Rs mn)	1,68,100	1,92,103	2,26,789
VNB (Rs mn)	50,700	54,749	64,635
Embedded Value (Rs mn)	4,60,600	5,51,496	6,60,003
VNB margin (%)	30.1	28.5	28.5
EVPS (Rs)	475.2	566.8	674.0
EPS (Rs)	17.2	17.7	19.2
Consensus EPS (Rs)	17.2	20.6	23.5
P/EV (x)	2.7	2.3	1.9

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional

Stock performance



Source: NSE



HOLD
 TP: Rs 2,500 | ▲ 10%

AMBER ENTERPRISES

Consumer Durables

26 July 2023

Topline wavers, margins progressing

- Q1 revenue weak given the “worst of bad seasons”, though margins improved on a better product mix
- Strategic shift towards components working in favour of Amber; mobility business offers a large opportunity
- TP raised to Rs 2,500 (vs. Rs 2,260) on rollover; maintain HOLD

Vinod Chari | Swati Jhunjunwala
 research@bobcaps.in

Revenue a miss, margins shine: Amber’s topline at Rs 17bn (-7% YoY) faltered due to unseasonal weather patterns and sluggish demand in the room air conditioner (RAC) business. On the other hand, EBITDA grew 33% YoY with 230bps margin expansion owing to a favourable change in product mix as the contribution of components increased.

Segmental performance: The RAC and components business (73% of revenue) declined 14% YoY during the quarter, while motors, electronics and mobility business grew by 5%, 28% and 9% respectively. Management expects the mobility business to grow rapidly amid burgeoning business opportunities.


Industry expected to grow ~8% in FY24: The AC industry had a poor first quarter on account of unseasonal rains during peak summer season which saw industry sale volumes decline 20-25%. However, management expects the industry to post full-year growth of 7-8% to ~9mn units, with Amber’s RAC business growing 3-4% ahead of the industry.

Upbeat guidance: Management has maintained its EBITDA growth guidance of 25-30% for FY24 and continues to expect above-market growth in the RAC business. The electronics, motors and mobility divisions are guided to grow by 35-40%, 20-25% and 15-20% respectively for the year, despite one of the worst seasons in Q1.

Soft RAC outlook: The structural shift in RAC manufacturing, where outsourcing has fallen to 30% in FY23 vs. 41% in FY21 due to production-linked incentive announcements, appears to have been offset by Amber’s prudent shift towards component manufacturing. That said, the RAC business remains beset by challenges from an unfavourable demand climate, competition and erratic weather.

Retain HOLD: We value the stock at an unchanged 27x P/E multiple – a 40% discount to the stock’s 3Y average – and roll valuations over to Jun’25E, leading to a revised TP of Rs 2,500 from Rs 2,260. Given the soft RAC outlook and limited upside potential post runup in Amber’s stock price, we retain HOLD.

Key changes



Ticker/Price	AMBER IN/Rs 2,265
Market cap	US\$ 928.6mn
Free float	60%
3M ADV	US\$ 6.4mn
52wk high/low	Rs 2,580/Rs 1,763
Promoter/FPI/DII	40%/24%/14%


Source: NSE | Price as of 25 Jul 2023

Key financials

Y/E 31 Mar	FY23P	FY24E	FY25E
Total revenue (Rs mn)	69,271	85,232	1,01,221
EBITDA (Rs mn)	4,179	5,173	6,343
Adj. net profit (Rs mn)	1,572	2,034	2,822
Adj. EPS (Rs)	46.7	60.4	83.8
Consensus EPS (Rs)	46.7	65.5	91.7
Adj. ROAE (%)	8.6	10.1	12.6
Adj. P/E (x)	48.5	37.5	27.0
EV/EBITDA (x)	18.3	14.7	12.0
Adj. EPS growth (%)	44.0	29.4	38.8

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional

Stock performance



Source: NSE



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (“US”) OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**
 Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**
 SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**
 Brand Name: **BOBCAPS**
 Trade Name: **www.barodaetrade.com**
 CIN: **U65999MH1996GOI098009**

Logo: 

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.
 Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.